June 3, 2019

Nordic Nanovector: European patent granted for Betalutin® or Humalutin® in combination with anti-CD20 antibodies for treating NHL

03.06.2019 07:00 Oslo, Norway 3 June 2019 Nordic Nanovector ASA (OSE: NANO) announces that the European Patent Organisation (EPO) has granted the company’s European...
Read more
June 3, 2019

Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination

June 3, 2019 Press release - Non-regulatory  Combination of ONCOS-102 and Keytruda reduces size of non-injected tumors    In vivo proof-of-concept of ONC...
Read more
June 3, 2019

Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)

-Targeted antibody elicits responses in both FGFR3 wild-type and mutant/fusion patients- -Favorable tolerability and safety profile and prolonged treatment duration- - Results pr...
Read more
May 29, 2019

Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude

Sustained, clinically meaningful bilateral improvement in visual functions 96 weeks after injection Observed bilateral improvement interpreted as clearly superior to known n...
Read more
May 23, 2019

Targovax to fully focus on ONCOS oncolytic virus program

Oslo, Norway, 23 May 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announc...
Read more
May 23, 2019

Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer

Oslo, Norway, 23 May 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announc...
Read more
May 23, 2019

Nordic Nanovector ASA – Results for the First Quarter 2019

Oslo, Norway, 23 May 2019 Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2019. A presentation by the company’s senior management team ...
Read more
May 21, 2019

MIPS acquires patent rights and the brand FLUID

May 21, 2019 MIPS, the world leader in brain protection systems within helmet-based safety, has today entered into an acquisition agreement for assets that further enhan...
Read more
May 21, 2019

Nordic Nanovector: Archer-1 phase 1b Betalutin®/rituximab combination trial advances to next cohort

Oslo, Norway, 21 May 2019 Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial...
Read more
May 21, 2019

CERAMENT® – Now Available Exclusively Through BONESUPPORT

Boston, US, 09.30 ET, 21 May 2019 – BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone voids, is now the exclusive distributor of CERAME...
Read more